Comorbidity of attention deficit hyperactivity disorder and alcohol use disorders in adults: Neurobiological mechanisms and modern approaches to therapy (literature review)

Comorbidity of attention deficit hyperactivity disorder and alcohol use disorders in adults: Neurobiological mechanisms and modern approaches to therapy (literature review)

 

Authors

 

V.Yu. Skryabin

State Budgetary Healthcare Institution “Moscow Scientific and Practical Center for Narcology of the Moscow City Health Department”, Moscow, Russian Federation

A.V. Masyakin

State Budgetary Healthcare Institution “Moscow Scientific and Practical Center for Narcology of the Moscow City Health Department”, Moscow, Russian Federation

V.P. Petrovsky

State Budgetary Healthcare Institution “Moscow Scientific and Practical Center for Narcology of the Moscow City Health Department”, Moscow, Russian Federation

S.I. Sokolova

State Budgetary Healthcare Institution “Moscow Scientific and Practical Center for Narcology of the Moscow City Health Department”, Moscow, Russian Federation

P.S. Makartseva

State Budgetary Healthcare Institution “Moscow Scientific and Practical Center for Narcology of the Moscow City Health Department”, Moscow, Russian Federation

 

https://doi.org/10.26617/1810-3111-2025-3(128)-69-82

 

Journal: Siberian Herald of Psychiatry and Addiction Psychiatry. 2025; 3 (128):  69-82.

 

Abstract

Introduction. Attention deficit hyperactivity disorder (ADHD) and alcohol use disorders (AUD) are common and clinically significant conditions that often occur concurrently and inevitably reduce the quality of life. In individuals with ADHD, the risk of developing AUD is significantly higher than in the general population, which is due to universal neurobiological, behavioral and psychosocial mechanisms. Objective: to summarize current data on the prevalence, pathogenesis, diagnosis and approaches to the treatment of ADHD and AUD comorbidity. Methods. A review of the scientific literature published in the PubMed, Scopus and RSCI scientometric databases was conducted, with an emphasis on the epidemiological, neurobiological, psychosocial and clinical diagnostic aspects of the interaction between ADHD and AUD. The paper includes English-language publications from 2000 to 2024, as well as Russian-language sources covering domestic experience in studying the problem. Results.The key factors contributing to the formation of comorbidity were identified: dopaminergic dysfunction, impulsivity, emotional dysregulation, stress effects, and disturbances in parent-child relationships. The difficulties in diagnosing ADHD in patients with AUD due to symptomatic overlap and cognitive impairment against the background of alcohol withdrawal were noted. The need for routine screening and integration of ADHD treatment into drug treatment practice was substantiated. Multimodal approaches were recognized as the most effective, including pharmacotherapy (including non-stimulating drugs without central nervous system activation and anti-craving agents to reduce cravings for psychoactive substances) and psychotherapeutic interventions (cognitive behavioral therapy as a tool for developing coping strategies). Conclusion. The comorbidity of ADHD and AUD requires a comprehensive interdisciplinary approach, including early diagnosis, individualized therapy to optimize treatment, and the elimination of systemic barriers to inpatient and outpatient psychiatric care. Future research should be aimed at clarifying the pathogenesis, developing personalized treatment strategies, and implementing comprehensive prevention programs in high-risk groups.

 

Keywords: ADHD; alcohol use disorders; comorbidity; impulsivity as a factor of maladaptation; diagnostics; pharmacotherapy; psychotherapy; dopamine system disorders.

 

Article (pdf)

 

Contacts

This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Materials 

For citation: Skryabin V.Yu., Masyakin A.V., Petrovsky V.P., Sokolova S.I., Makartseva P.S. Comorbidity of attention deficit hyperactivity disorder and alcohol use disorders in adults: Neurobiological mechanisms and modern approaches to therapy (literature review). Siberian Herald of Psychiatry and Addiction Psychiatry.2025; 3 (128): 69-82. https://doi.org/10.26617/1810-3111-2025-3(128)-69-82

 

REFERENCES

  1. Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics. 2015 Apr;135(4):e994-1001. https://doi.org/10.1542/peds.2014-3482. Epub 2015 Mar 2. PMID: 25733754.
  2. Fayyad J, Sampson NA, Hwang I, Adamowski T, Aguilar-Gaxiola S, Al-Hamzawi A, Andrade LH, Borges G, de Girolamo G, Florescu S, Gureje O, Haro JM, Hu C, Karam EG, Lee S, Navarro-Mateu F, O'Neill S, Pennell BE, Piazza M, Posada-Villa J, Ten Have M, Torres Y, Xavier M, Zaslavsky AM, Kessler RC; WHO World Mental Health Survey Collaborators. The descriptive epidemiology of DSM-IV Adult ADHD in the World Health Organization World Mental Health Surveys. Atten Defic Hyperact Disord. 2017 Mar;9(1):47-65. https://doi.org/10.1007/s12402-016-0208-3. Epub 2016 Nov 19. PMID: 27866355; PMCID: PMC5325787.
  3. Palmini A. Attention-deficit/hyperactivity disorder (ADHD) in adults: a multilayered approach to a serious disorder of inattention to the future. Arq Neuropsiquiatr. 2024 Jul;82(7):1-12. https://doi.org/10.1055/s-0044-1791513. Epub 2024 Oct 2. PMID: 39357854; PMCID: PMC11500298.
  4. Groenman AP, Schweren LJS, Weeda W, Luman M, Noordermeer SDS, Heslenfeld DJ, Franke B, Faraone SV, Rommelse N, Hartman CA, Hoekstra PJ, Buitelaar J, Oosterlaan J. Stimulant treatment profiles predicting co-occurring substance use disorders in individuals with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2019 Sep;28(9):1213-1222. https://doi.org/10.1007/s00787-019-01283-y. Epub 2019 Feb 5. PMID: 30721356; PMCID: PMC6751155.
  5. Dalsgaard S, Mortensen PB, Frydenberg M, Thomsen PH. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood ‒ a naturalistic long-term follow-up study. Addict Behav. 2014 Jan;39(1):325-8. https://doi.org/10.1016/j.addbeh.2013.09.002. Epub 2013 Sep 10. PMID: 24090624.
  6. Global status report on alcohol and health and treatment of substance use disorders. Geneva: World Health Organization, 2024:312. https:///creativecommons.org/licenses/by-nc-sa/3.0/igo).
  7. American Psychiatric Association, DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5™ (5th ed.). American Psychiatric Publishing, Inc. (2013).https://doi.org/10.1176/appi.books.9780890425596.
  8. Knox J, Hasin DS, Larson FRR, Kranzler HR. Prevention, screening, and treatment for heavy drinking and alcohol use disorder. Lancet Psychiatry. 2019 Dec;6(12):1054-1067. https://doi.org/10.1016/S2215-0366(19)30213-5. Epub 2019 Oct 17. PMID: 31630982; PMCID: PMC6883141.
  9. Kraus L, Seitz NN, Shield KD, Gmel G, Rehm J. Quantifying harms to others due to alcohol consumption in Germany: a register-based study. BMC Med. 2019 Mar 19;17(1):59. https://doi.org/10.1186/s12916-019-1290-0. PMID: 30885214; PMCID: PMC6423764.
  10. International Classification of Diseases Eleventh Revision (ICD-11). Geneva: World Health Organization; 2022:452. https://creativecommons.org/licenses/bynd/3.0/igo/ .
  11. Luderer M, Ramos Quiroga JA, Faraone SV, Zhang James Y, Reif A. Alcohol use disorders and ADHD. Neurosci Biobehav Rev. 2021 Sep;128:648-660. https://doi.org/10.1016/j.neubiorev.2021.07.010. Epub 2021 Jul 12. Erratum in: Neurosci Biobehav Rev. 2021 Nov;130:227. https://doi.org/10.1016/j.neubiorev.2021.08.026. PMID: 34265320.
  12. Daigre C, Roncero C, Rodríguez-Cintas L, Ortega L, Lligoña A, Fuentes S, Pérez-Pazos J, Martínez-Luna N, Casas M. Adult ADHD screening in alcohol-dependent patients using the Wender-Utah Rating Scale and the adult ADHD Self-Report Scale. J Atten Disord. 2015 Apr;19(4):328-34. https://doi.org/10.1177/1087054714529819. Epub 2014 Apr 17. PMID: 24743975.
  13. Luderer M, Sick C, Kaplan-Wickel N, Reinhard I, Richter A, Kiefer F, Weber T. Prevalence estimates of ADHD in a sample of inpatients with alcohol dependence. J Atten Disord. 2020 Dec;24(14):2072-2083. https://doi.org/10.1177/1087054717750272. Epub 2018 Jan 7. PMID: 29308693.
  14. Pedersen CB, Mors O, Bertelsen A, Waltoft BL, Agerbo E, McGrath JJ, Mortensen PB, Eaton WW. A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry. 2014 May;71(5):573-81. https://doi.org/10.1001/jamapsychiatry.2014.16. PMID: 24806211.
  15. Groenman AP, Janssen TWP, Oosterlaan J. Childhood psychiatric disorders as risk factor for subsequent substance abuse: A meta-analysis. J Am Acad Child Adolesc Psychiatry. 2017 Jul;56(7):556-569. https://doi.org/10.1016/j.jaac.2017.05.004. Epub 2017 May 11. PMID: 28647007.
  16. Howard AL, Molina BS, Swanson JM, Hinshaw SP, Belendiuk KA, Harty SC, Arnold LE, Abikoff HB, Hechtman L, Stehli A, Greenhill LL, Newcorn JH, Wigal T. Developmental progression to early adult binge drinking and marijuana use from worsening versus stable trajectories of adolescent attention deficit/hyperactivity disorder and delinquency. Addiction. 2015 May;110(5):784-95. https://doi.org/10.1111/add.12880. Epub 2015 Mar 24. PMID: 25664657; PMCID: PMC4398637.
  17. Wilens TE. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am. 2004 Jun;27(2):283-301. https://doi.org/10.1016/S0193-953X(03)00113-8. PMID: 15063998.
  18. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, Baldursson G, Belliveau R, Bybjerg-Grauholm J, Bækvad-Hansen M, Cerrato F, Chambert K, ChurchhouseC, Dumont A, Eriksson N, Gandal M, Goldstein JI, Grasby KL, Grove J, Gudmundsson OO, Hansen CS, Hauberg ME, Hollegaard MV, Howrigan DP, Huang H, Maller JB, Martin AR, Martin NG, Moran J, Pallesen J, Palmer DS, Pedersen CB, Pedersen MG, Poterba T, Poulsen JB, Ripke S, Robinson EB, Satterstrom FK, Stefansson H, Stevens C, Turley P, Walters GB, Won H, Wright MJ; ADHD Working Group of the Psychiatric Genomics Consortium (PGC); Early Lifecourse& Genetic Epidemiology (EAGLE) Consortium; 23andMe Research Team; Andreassen OA, Asherson P, Burton CL, Boomsma DI, Cormand B, Dalsgaard S, Franke B, Gelernter J, Geschwind D, Hakonarson H, Haavik J, Kranzler HR, Kuntsi J, Langley K, Lesch KP, Middeldorp C, Reif A, Rohde LA, Roussos P, Schachar R, Sklar P, Sonuga-Barke EJS, Sullivan PF, Thapar A, Tung JY, Waldman ID, Medland SE, Stefansson K, Nordentoft M, Hougaard DM, Werge T, Mors O, Mortensen PB, Daly MJ, Faraone SV, Børglum AD, Neale BM. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet. 2019 Jan;51(1):63-75. https://doi.org/10.1038/s41588-018-0269-7. Epub 2018 Nov 26. PMID: 30478444; PMCID: PMC6481311.
  19. Koob GF, Volkow ND. Neurobiology of addiction: A neurocircuitry analysis. Lancet Psychiatry. 2016 Aug;3(8):760-773. https://doi.org/10.1016/S2215-0366(16)00104-8. PMID: 27475769; PMCID: PMC6135092.
  20. French B, Nalbant G, Wright H, Sayal K, Daley D, Groom MJ, Cassidy S, Hall CL. The impacts associated with having ADHD: an umbrella review. Front Psychiatry. 2024 May 21;15:1343314. https://doi.org/10.3389/fpsyt.2024.1343314. PMID: 38840946; PMCID: PMC11151783.
  21. Yoshimura A, Matsushita S, Kimura M, Yoneda JI, Maesato H, Yokoyama A, Higuchi S. Influence of ADHD, especially attention-deficit characteristics, on the course of alcohol-dependent individuals. BMC Psychiatry. 2022 Dec 19;22(1):803. https://doi.org/10.1186/s12888-022-04455-4. PMID: 36536366; PMCID: PMC9762023.
  22. Müller CP, Schumann G, Rehm J, Kornhuber J, Lenz B. Self-management with alcohol over lifespan: psychological mechanisms, neurobiological underpinnings, and risk assessment. Mol Psychiatry. 2023 Jul;28(7):2683-2696. https://doi.org/10.1038/s41380-023-02074-3. PMID: 37117460; PMCID: PMC10615763.
  23. Li C, Palka JM, Brown ES. Cognitive impairment in individuals with bipolar disorder with and without comorbid alcohol and/or cocaine use disorders. J Affect Disord. 2020 Jul 1;272:355-362. https://doi.org/10.1016/j.jad.2020.03.179. Epub 2020 Apr 29. PMID: 32553378; PMCID: PMC7305419.
  24. Martinotti G, Lupi M, Acciavatti T, Cinosi E, Santacroce R, Signorelli MS, Bandini L, Lisi G, Quattrone D, Ciambrone P, Aguglia A, Pinna F, Calò S, Janiri L, di Giannantonio M. Novel psychoactive substances in young adults with and without psychiatric comorbidities. Biomed Res Int. 2014;2014:815424. https://doi.org/10.1155/2014/815424. Epub 2014 Jul 15. PMID: 25133182; PMCID: PMC4123484.
  25. OvsyannikovMV, PodgornovIS, UmakhadzhievDSh. The relationship between attention deficit hyperactivity disorder and addictive disorders. Universum: Medicine and Pharmacology. 2022;5(88):4-6 (in Russian).
  26. Crunelle CL, van den Brink W, Moggi F, Konstenius M, Franck J, Levin FR, van de Glind G, Demetrovics Z, Coetzee C, Luderer M, Schellekens A; ICASA consensus group; Matthys F. International Consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit/hyperactivity disorder. Eur Addict Res. 2018;24(1):43-51. https://doi.org/10.1159/000487767. Epub 2018 Mar 6. PMID: 29510390; PMCID: PMC5986068.
  27. Wardell JD, Quilty LC, Hendershot CS. Impulsivity, working memory, and impaired control over alcohol: A latent variable analysis. Psychol Addict Behav. 2016 Aug;30(5):544-554. https://doi.org/10.1037/adb0000186. Epub 2016 Jun 6. PMID: 27269291; PMCID: PMC5266597.
  28. van de Glind G, Konstenius M, Koeter MWJ, van Emmerik-van Oortmerssen K, Carpentier PJ, Kaye S, Degenhardt L, Skutle A, Franck J, Bu ET, Moggi F, Dom G, Verspreet S, Demetrovics Z, Kapitány-Fövény M, Fatséas M, Auriacombe M, Schillinger A, Møller M, Johnson B, Faraone SV, Ramos-Quiroga JA, Casas M, Allsop S, Carruthers S, Schoevers RA, Wallhed S, Barta C, Alleman P; IASP Research Group; Levin FR, van den Brink W. Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: Results from an international multi-center study exploring DSM-IV and DSM-5 criteria. Drug Alcohol Depend. 2014 Jan 1;134:158-166. https://doi.org/10.1016/j.drugalcdep.2013.09.026. Epub 2013 Oct 5. PMID: 24156882; PMCID: PMC4133781.
  29. Luderer M, Kaplan-Wickel N, Richter A, Reinhard I, Kiefer F, Weber T. Screening for adult attention-deficit/hyperactivity disorder in alcohol dependent patients: Underreporting of ADHD symptoms in self-report scales. Drug Alcohol Depend. 2019 Feb 1;195:52-58.https://doi.org/10.1016/j.drugalcdep.2018.11.020. Epub 2018 Dec 10. PMID: 30583265.
  30. Kooij JJS, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, Thome J, Dom G, Kasper S, Nunes Filipe C, Stes S, Mohr P, Leppämäki S, Casas M, Bobes J, Mccarthy JM, Richarte V, KjemsPhilipsen A, Pehlivanidis A, Niemela A, Styr B, Semerci B, Bolea-Alamanac B, Edvinsson D, Baeyens D, Wynchank D, Sobanski E, Philipsen A, McNicholas F, Caci H, Mihailescu I, Manor I, Dobrescu I, Saito T, Krause J, Fayyad J, Ramos-Quiroga JA, Foeken K, Rad F, Adamou M, Ohlmeier M, Fitzgerald M, Gill M, Lensing M, MotavalliMukaddes N, Brudkiewicz P, Gustafsson P, Tani P, Oswald P, Carpentier PJ, De Rossi P, Delorme R, MarkovskaSimoska S, Pallanti S, Young S, Bejerot S, Lehtonen T, Kustow J, Müller-Sedgwick U, Hirvikoski T, Pironti V, Ginsberg Y, Félegyházy Z, Garcia-Portilla MP, Asherson P. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019 Feb;56:14-34. https://doi.org/10.1016/j.eurpsy.2018.11.001.Epub 2018 Nov 16. PMID: 30453134.
  31. Weafer J, Fillmore MT, Milich R. Increased sensitivity to the disinhibiting effects of alcohol in adults with ADHD. Exp Clin Psychopharmacol. 2009 Apr;17(2):113-21. https://doi.org/10.1037/a0015418. PMID: 19331488; PMCID: PMC2787090.
  32. Henges AL, Marczinski CA. Impulsivity and alcohol consumption in young social drinkers. Addict Behav. 2012 Feb;37(2):217-20. https://doi.org/10.1016/j.addbeh.2011.09.013.
  33. Farré-Colomés À, Gerhardt S, Luderer M, Sobanski E, Kiefer F, Vollstädt-Klein S. Common and distinct neural connectivity in attention-deficit/hyperactivity disorder and alcohol use disorder studied using resting-state functional magnetic resonance imaging. Alcohol Clin Exp Res. 2021 May;45(5):948-960. https://doi.org/10.1111/acer.14593. PMID: 33690916.
  34. Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, Fowler JS, Zhu W, Logan J, Ma Y, Pradhan K, Wong C, Swanson JM. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. 2009 Sep 9;302(10):1084-91. https://doi.org/10.1001/jama.2009.1308. Erratum in: JAMA. 2009 Oct 7;302(13):1420. PMID: 19738093; PMCID: PMC2958516.
  35. Barbuti M, Maiello M, Spera V, Pallucchini A, Brancati GE, Maremmani AGI, Perugi G, Maremmani I. Challenges of treating ADHD with comorbid substance use disorder: Considerations for the clinician. J Clin Med. 2023 Apr 24;12(9):3096. https://doi.org/10.3390/jcm12093096. PMID: 37176536; PMCID: PMC10179386.
  36. Cortese S. Pharmacologic treatment of attention deficit-hyperactivity disorder. N Engl J Med. 2020 Sep 10;383(11):1050-1056. https://doi.org/10.1056/NEJMra1917069. PMID: 32905677.
  37. Luderer M, Reinhard I, Richter A, Kiefer F, Weber T. ADHD Is associated with a higher risk for traumatic events, self-reported PTSD, and a higher severity of PTSD symptoms in alcohol-dependent patients. Eur Addict Res. 2020;26(4-5):245-253. https://doi.org/10.1159/000508918. Epub 2020 Jul 10. PMID: 32653887.
  38. Anker E, Haavik J, Heir T. Alcohol and drug use disorders in adult attention-deficit/hyperactivity disorder: Prevalence and associations with attention-deficit/hyperactivity disorder symptom severity and emotional dysregulation. World J Psychiatry. 2020 Sep 19;10(9):202-211. https://doi.org/10.5498/wjp.v10.i9.202. PMID: 33014721; PMCID: PMC7515748.
  39. Acar S, Aktaş Y. The dynamics of the relationship between attention deficit hyperactivity disorder and alcohol use disorder. Addicta: Turk J Addict. 2024 Dec 11;11(3):407-13. https://doi.org/10.5152/ADDICTA.2024.24203.
  40. Wilens TE. Attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry. 2006 Dec;163(12):2059-63.https://doi.org/10.1176/ajp.2006.163.12.2059. PMID: 17151154.
  41. Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, Newcorn JH, Gignac M, Al Saud NM, Manor I, Rohde LA, Yang L, Cortese S, Almagor D, Stein MA, Albatti TH, Aljoudi HF, Alqahtani MMJ, Asherson P, Atwoli L, Bölte S, Buitelaar JK, Crunelle CL, Daley D, Dalsgaard S, Döpfner M, Espinet S, Fitzgerald M, Franke B, Gerlach M, Haavik J, Hartman CA, Hartung CM, Hinshaw SP, Hoekstra PJ, Hollis C, Kollins SH, Sandra Kooij JJ, Kuntsi J, Larsson H, Li T, Liu J, Merzon E, Mattingly G, Mattos P, McCarthy S, Mikami AY, Molina BSG, Nigg JT, Purper-Ouakil D, Omigbodun OO, Polanczyk GV, Pollak Y, Poulton AS, Rajkumar RP, Reding A, Reif A, Rubia K, Rucklidge J, Romanos M, Ramos-Quiroga JA, Schellekens A, Scheres A, Schoeman R, Schweitzer JB, Shah H, Solanto MV, Sonuga-Barke E, Soutullo C, Steinhausen HC, Swanson JM, Thapar A, Tripp G, van de Glind G, van den Brink W, Van der Oord S, Venter A, Vitiello B, Walitza S, Wang Y. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. NeurosciBiobehav Rev. 2021 Sep;128:789-818. https://doi.org/10.1016/j.neubiorev.2021.01.022. Epub 2021 Feb 4. PMID: 33549739; PMCID: PMC8328933.
  42. Waltereit J, Uhlmann A, Tarassidis C, Preuss U, Roessner V, Waltereit R. Treatment of affective dysregulation in ADHD with guanfacine: study protocol. Front Child Adolesc Psychiatry. 2025 Mar 28;4:1547672. https://doi.org/10.3389/frcha.2025.1547672. PMID: 40226438; PMCID: PMC11985798.
  43. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD001867. https://doi.org/10.1002/14651858.CD001867.pub3. PMID: 21154349.
  44. Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010 Sep 8;(9):CD004332. https://doi.org/10.1002/14651858.CD004332.pub2.PMID: 20824837; PMCID: PMC12147086.
  45. Martinotti G, Lupi M, Sarchione F, Santacroce R, Salone A, De Berardis D, Serroni N, Cavuto M, Signorelli M, Aguglia E, Valchera A, Iasevoli F, Di Giannantonio M. The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview. Curr Pharm Des. 2013;19(35):6367-74. https://doi.org/10.2174/13816128113199990425. PMID: 23782139.
  46. Bazil CW, Dave J, Cole J, Stalvey J, Drake E. Pregabalin increases slow-wave sleep and may improve attention in patients with partial epilepsy and insomnia. Epilepsy Behav. 2012 Apr;23(4):422-5. https://doi.org/10.1016/j.yebeh.2012.02.005. Epub 2012 Mar 14. PMID: 22424859.